Abbott Laboratories Second-Quarter Results Beat Expectations Despite Lower COVID-19 Testing Sales
The company now anticipates about $1.3 billion in sales from COVID-19 testing products for 2023, compared with the prior forecast of $1.5 billion, "due to current testing dynamics, including lower demand for testing following the end of the public health emergency in May," Chief Financial Officer Robert Funck said on the call.
For the third quarter, Abbott anticipates adjusted earnings of roughly $1.10 per share, according to Funck. Analysts estimate EPS of $1.11.
Technicals:
Cycle Sniper Reversal Filter Headed Nort
Cycle Sniper Bullish ddeviation
Key Resistance: 116 $
Closing above 116 $
Targets: 122 $ and 128 $
The company now anticipates about $1.3 billion in sales from COVID-19 testing products for 2023, compared with the prior forecast of $1.5 billion, "due to current testing dynamics, including lower demand for testing following the end of the public health emergency in May," Chief Financial Officer Robert Funck said on the call.
For the third quarter, Abbott anticipates adjusted earnings of roughly $1.10 per share, according to Funck. Analysts estimate EPS of $1.11.
Technicals:
Cycle Sniper Reversal Filter Headed Nort
Cycle Sniper Bullish ddeviation
Key Resistance: 116 $
Closing above 116 $
Targets: 122 $ and 128 $
For alerts,charts,special reports,news and singals over 15.000 + instruments contact us via pm or our free Discord: discord.gg/Ku9kzfq
Link to services and products: linktr.ee/chartreaderpro
Link to services and products: linktr.ee/chartreaderpro